Yeruusaalem, 19ka Nofeembar, 2025 (TPS-IL) — Rafa Laboratories, oo ah shirkad Yeruusaalem ka dhisan oo horumarisa xalalka difaaca bayoolojiga iyo daaweynta degdegga ah, ayaa lagu abaalmariyay qandaraas dhan ilaa $186 milyan oo doolar oo ka yimid Maamulka Horumarinta Cilmi-baarista Bayomedical-ka ee Mareykanka (BARDA) si loo horumariyo qaab cusub oo la duri karo muruqa ah oo tranexamic acid (TXA) ah. Daaweyntani waxa loogu talagalay daaweynta degdegga ah ee dhiig-baxa nafta halis gelinaya ee ka dhaca goobaha degdegga ah, taas oo ka jawaabeysa baahi weyn oo ku jirta xaaladaha dhaawaca daran iyo kuwa dad badan waxyeeloobeen.
Rafa ayaa sheegtay in nooca, kaas oo si toos ah loo durayo muruqa, uu fududeyn karo maamulkiisa marka la barbar dhigo TXA-da hadda la isticmaalo ee xididada, waxaana laga yaabaa in lagu lammaaniyo autoinjector.
Heshiiskan ayaa calaamadeynaya iskaashigii labaad ee ugu weynaa ee Rafa la yeesho BARDA.